



US006369116B1

(12) **United States Patent**
Wong et al.

(10) Patent No.: **US 6,369,116 B1**
(45) Date of Patent: **Apr. 9, 2002**

(54) **COMPOSITION AND METHOD FOR
TREATING GLAUCOMA**

(75) Inventors: **Vernon Wong, Menlo Park; Lin Peng,**
San Jose, both of CA (US)

(73) Assignee: **Oculex Pharmaceuticals, Inc.,**
Sunnyvale, CA (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/221,002**

(22) Filed: **Dec. 23, 1998**

Related U.S. Application Data

(63) Continuation of application No. 09/160,635, filed on Sep.
24, 1998, which is a continuation of application No. 08/459,
134, filed on Jun. 2, 1995, now Pat. No. 5,869,079.

(51) Int. Cl.⁷ **A01N 43/38**

(52) U.S. Cl. **514/913; 424/486; 424/488**

(58) Field of Search **424/484, 486,**
424/488; 514/944, 913

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,478,818 A 10/1984 Shell et al. 424/14
4,863,457 A * 9/1989 Lee
4,865,846 A * 9/1989 Kaufman
4,997,652 A 3/1991 Wong 424/428
5,075,115 A 12/1991 Brine 424/486
5,164,188 A 11/1992 Wong 424/428
5,268,178 A * 12/1993 Calhoun et al.
5,356,629 A 10/1994 Sander et al. 424/422
5,385,887 A 1/1995 Yim et al. 514/12
5,501,856 A 3/1996 Ohtori et al. 424/428
5,656,297 A * 8/1997 Bernstein et al.
5,707,643 A * 1/1998 Ogura

OTHER PUBLICATIONS

R. Baker, "Controlled Release of Biologically Active
Agents," *A Wiley-Interscience Publication*, p. 73 (1987).

G. DiColo, "Controlled drug release from implantable matri-
ces based on hydrophobic polymers," *Biomaterials* 1992,
vol. 13, No. 12:850-853.

T. Jackanicz et al, "Polylactic Acid As A Biodegradable
Carrier For Contraceptive Steroids," *Contraception*, vol. 8,
No. 3:227-235.

R. Miller et al, "Degradation Rates of Oral Resorbable
Implants (Polylactates and Polyglycolates): Rate Modifica-
tion with Changes in PLA/PGA Copolymer Ratios," *J.*
Biomed. Mater. Res., vol. 11:711-719 (1977).

J. Heller, "Biodegradable Polymers in Controlled Drug
Delivery," *CRC Critical Reviews in Therapeutic Drug Car-
rier Systems*, vol. 1, Issue 1:39-90.

J. Charles, et al, "Use of Bioerodible Polymers Impregnated
with Mitomycin in Glaucoma Filtration Surgery in Rabbits,"
Ophthalmology, Apr. 1991, vol. 98, No. 4: 503-508.

H. Jampel, et al, "Glaucoma Filtration Surgery in Monkeys
Using 5-Fluorouridine in Polyanhydride Disks," *Arch Oph-
thalmol*, Mar. 1990, vol. 108:430-435.

D. Lee, et al, "The Use of Bioerodible Polymers and
5-Fluorouracil in Glaucoma Filtration Surgery," *Investiga-
tive Ophthalmology & Visual Science*, Nov. 1988, vol. 29,
No. 11:1692-1697.

M. Chang, et al, "Basic Science and Clinical Aspects of
Wound Healing in Glaucoma Filtering Surgery," *Journal of*
Ocular Pharmacology and Therapeutics, 1998, vol. 14, No.
1:75-95.

D. Lee, et al, "Glaucoma Filtration Surgery in Rabbits Using
Bioerodible Polymers and 5-Fluorouracil," *Ophthalmol-
ogy*, Dec. 1987, vol. 94, No. 12:1523-1530.

T. Smith, et al, "Sustained-release subconjunctival 5-Fluo-
rouracil," *Ophthalmic Surgery Lasers*, Sep. 1996, vol. 27,
No. 9:763-767.

* cited by examiner

Primary Examiner—Edward J. Webman

(74) Attorney, Agent, or Firm—David J. Brezner; Todd A.
Lorenz; Flehr Hohbach Test Albritton & Herbert LLP

(57)

ABSTRACT

Implants and methods are provided for modulating wound
healing and controlling infection to improve the success of
glaucoma filtration surgery. Formulations of one or more
therapeutically active agents and a biodegradable polymer
provide a substantially constant rate of release for an
extended period of time.

19 Claims, 5 Drawing Sheets

